Last reviewed · How we verify
NCT05614986: Neurcog TAVR
Prospective Evaluation of Neurocognition in Patients Undergoing Transcatheter Aortic Valve Replacement
trial testing 5 minute Montreal Cognitive Assessment (mini MoCA) in Mild Cognitive Impairment in 81 participants. Completed in 27 February 2024.
2 October 2023
Quick facts
| Lead sponsor | Baylor Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 81 |
| Start date | 17 January 2022 |
| Primary completion | 2 October 2023 |
| Estimated completion | 27 February 2024 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- 5 minute Montreal Cognitive Assessment (mini MoCA)
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Aortic Stenosis — all drugs for Aortic Stenosis →
Sponsor
Baylor Research Institute
Who can join
18 and older, any sex, with Mild Cognitive Impairment or Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trail is for patients with mild cognitive impairment (MCI) who are receiving a transcatheter aortic valve replacement (TAVR). We will assess changes in neurocognition following TAVR with the 5 minute Montreal Cognitive Assessment (mini MoCA) when comparing pre procedure with post procedure assessments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05614986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other Baylor Research Institute trials
Trials by the same sponsor.
- NCT07467720 — Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial · NA · not yet recruiting
- NCT07547878 — Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) · Phase 4 · not yet recruiting
- NCT07460583 — ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes · NA · not yet recruiting
- NCT07096544 — CALM Study: Cardiomems Assisted Lvad Management · NA · not yet recruiting
- NCT07220395 — eHealth Literacy Intervention for Spanish Speaking Older Adults in the US · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05614986 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baylor Research Institute
- Last refreshed: 27 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05614986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing